Resensitization to Nivolumab after Intratumoral Chemotherapy in Recurrent Head and Neck Squamous Cell Cancer: A Report of 2 Cases.
Abscopal-like effect
Head and neck cancer
Intratumoral chemotherapy
Nivolumab
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
17
04
2020
accepted:
18
04
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
The survival of patients with head and neck squamous cancer with locoregional recurrence is short if salvage surgery or radiation cannot be performed. Systemic chemotherapy based on platinum salts and cetuximab produces only partial and transient responses. Immune checkpoint inhibitors (i.e., nivolumab) lead to a low complete response rate of only about 10%, but in some cases the effects can be long-lasting. Intratumoral chemotherapy (ITC) has been proposed for patients with local recurrence of head and neck squamous cell carcinoma with an objective response rate of 27-50%. However, it often leads to peritumoral tissue necrosis, and the duration of local control is limited. Here, we present 2 patients with head and neck squamous cell cancer whose local recurrences were refractory to intravenous chemotherapy and nivolumab. ITC using nonnecrotizing molecules, associated with nivolumab, led to complete stable local and distant response. ITC seems to trigger tumor resensitization to previously ineffective immunotherapy. This combination deserves an evaluation in the framework of a prospective trial.
Identifiants
pubmed: 32884527
doi: 10.1159/000507986
pii: cro-0013-0835
pmc: PMC7443634
doi:
Types de publication
Case Reports
Langues
eng
Pagination
835-842Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Eur J Cancer. 2015 Oct;51(15):2130-2143
pubmed: 26421817
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Semin Oncol. 2015 Aug;42(4):601-16
pubmed: 26320064
Ann Otolaryngol Chir Cervicofac. 2007 Jun;124(2):53-60
pubmed: 17434136
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Br J Cancer. 2005 Apr 25;92(8):1341-8
pubmed: 15846296
Nat Rev Clin Oncol. 2011 Mar;8(3):151-60
pubmed: 21364688
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
ESMO Open. 2018 Jan 9;3(1):e000257
pubmed: 29344407
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Oncoimmunology. 2020 Jan 9;9(1):1703449
pubmed: 32002302
Ann Otol Rhinol Laryngol. 2004 Mar;113(3 Pt 1):229-33
pubmed: 15053208